Bleeding risk and major adverse events in patients with cancer on oral anticoagulation therapy

Yong Joon Lee, Jin Kyu Park, Jae Sun Uhm, Jong Yun Kim, Hui Nam Pak, Moon Hyoung Lee, Jung Hoon Sung, Boyoung Joung

Research output: Contribution to journalArticlepeer-review

32 Citations (Scopus)


Background: The efficacy of oral anticoagulation therapy (OAT) has not been revealed in atrial fibrillation (AF) patients with newly diagnosed cancers. This study evaluated the thromboembolic and bleeding events in AF patients with malignancies according to OAT. Methods and results: In 2168 consecutive non-valvular AF patients with newly diagnosed malignancies, we analyzed the composite endpoints including major adverse cardiac events (MACEs) and major bleeding. Based on a propensity score matching, two groups with 690 matched pairs were created. Patient baseline characteristics were comparable between the matched groups. During a follow-up period of 3.9 ± 2.8 years, 72 (10%) and 65 (9%) patients had MACEs in the propensity score-matched OAT+ and OAT- groups, respectively (p = 0.461). There was no significant difference in the major bleeding (10% vs. 8%, p = 0.300) and composite endpoints (18% vs. 16%, p = 0.181) between OAT+ and OAT- patients. During the first year after the cancer diagnosis, 66 (48%) MACEs, 52 (41%) major bleedings, and 116 (49%) composite end points of all events occurred. The optimal international normalized ratio (2.0 to 3.0) level was achieved in only 85 (12%) patients. However, 1 year after cancer diagnosis, OAT+ patients with the target therapeutic range of ≥60% demonstrated better cumulative survival free of composite end point than OAT- patients (p = 0.026). Conclusion: During the first year after the cancer diagnosis, OAT did not improve the composite end point because of poor INR control caused by cancer treatment. However, after 1 year after diagnosis of cancer, optimal anticoagulation significantly reduced the composite end point.

Original languageEnglish
Pages (from-to)372-378
Number of pages7
JournalInternational Journal of Cardiology
Publication statusPublished - 2016 Jan 15

Bibliographical note

Funding Information:
This study was supported in part by research grants from the Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Education, Science and Technology ( NRF-2012R1A2A2A02045367 ), and a grant from the Korean Healthcare technology R&D project funded by Ministry of Health & Welfare ( HI12C1552 ).

Publisher Copyright:
© 2015 Elsevier Ireland Ltd. All rights reserved.

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Bleeding risk and major adverse events in patients with cancer on oral anticoagulation therapy'. Together they form a unique fingerprint.

Cite this